BPC-157: What Does the Human Evidence Actually Show?

Search for BPC-157 and you will find extraordinary claims: tendon and ligament healing, muscle recovery, gut repair, nerve regeneration, less inflammation, faster recovery from almost any injury. There is a reason those claims exist, because BPC-157 has a surprisingly large body of animal research behind it. What tends to disappear from social media is the other half of the story. The published human evidence for BPC-157 is tiny, and that contradiction sits at the heart of everything written about it.

What is BPC-157?

BPC-157 is a synthetic peptide of 15 amino acids with the sequence GEPPPGKPADDAGLV. The name is usually expanded as Body Protection Compound 157, and you may also see it as BPC 157, pentadecapeptide BPC-157, PL 14736, PL-10 or PLD-116.

It is commonly described as a fragment of a protein found in human gastric juice. That origin has never been confirmed by an independent laboratory: the parent protein has not been isolated, sequenced or deposited in any protein database. BPC-157 is best thought of as a synthetic research peptide of uncertain natural origin.

The research was built largely by one group in Zagreb and its collaborators. The Croatian drug company Pliva developed it as PL 14736 and ran early trials in ulcerative colitis in the early 2000s, but no efficacy or safety report from that programme has ever appeared in the peer reviewed literature. Later reviews from the originating group describe it as safe in those trials ¹, a claim that cannot be checked.

Why is BPC-157 so popular?

Because the animal results are unusually broad. Researchers have reported effects in experimental models involving tendons, ligaments, muscle, bone, the gut, blood vessels and parts of the nervous system Animal ². A 2025 systematic review of the musculoskeletal research found consistent reports of structural, functional or biomechanical improvement after injury in animals ³. That is real research, and almost all of it was preclinical.

How might BPC-157 work?

BPC-157 has no identified receptor. After three decades of research nobody has shown what it binds to, so its effects are described as changes across several pathways involved in repair:

• Blood vessel growth and nitric oxide. In endothelial cells it increases VEGFR2 signalling, and in animals it appears to balance the nitric oxide system rather than simply drive it Mechanistic.
• Tendon cells. In rat tendon fibroblasts it increased cell outgrowth, survival and migration through the FAK-paxillin pathway In vitro Animal ⁴, and raised growth hormone receptor levels In vitro ⁵.
• Gut and inflammation. In animal models it protects the stomach and gut lining against NSAID and alcohol injury and dampens inflammatory signalling Animal.

Put simply, in the laboratory and in animals BPC-157 appears to change some of the cellular processes involved in repairing damaged tissue. Showing that a peptide influences pathways linked to healing is not the same as showing that it heals human injuries. Mechanism tells you why something might work; clinical trials tell you whether it does.

What does the animal evidence show?

Quite a lot. Animal studies after tendon, muscle, ligament, bone and gut injuries report faster repair, better tissue organisation or improved function, which is why calling BPC-157 made up would be wrong. There is genuine biology worth investigating.

There are two problems. Animal results do not automatically carry over to humans, and a large share of the literature comes from a fairly concentrated network of researchers, many linked to Zagreb. Independent replication is one of science's main safeguards, and the more striking an apparent effect, the more that confirmation matters.

How much human research actually exists?

Very little. A 2026 review in Pharmaceutics concluded that the published human evidence comes to fewer than 30 subjects across three uncontrolled pilot studies, none of which used standardised pharmaceutical preparations, and that no phase 2 trial has been completed ⁶. For a substance discussed so confidently online, that is a very small evidence base. Here are the three studies.

Knee pain

A retrospective study contacted 16 people who had received injections into the knee for chronic knee pain Human ⁷. Twelve had received BPC-157 alone and 11 of them reported significant improvement; four had received BPC-157 with thymosin beta-4 and three of them improved.

The limitations are serious. The study was small and retrospective, with no randomisation and no placebo group. The diagnoses varied, some people received a combination rather than BPC-157 alone, and the outcome relied on people recalling their symptoms. A positive result in that setting is interesting. It is not evidence that BPC-157 repairs human tendons, cartilage or ligaments. The 2025 systematic review counted a single clinical study, a small retrospective knee series, among the 36 papers it included; the other 35 were preclinical.

Bladder pain

A second small study gave a single BPC-157 injection to 12 women with interstitial cystitis, a chronic bladder pain condition Human ⁸. Ten reported complete resolution of symptoms and two reported around 80% improvement, with no adverse events recorded. Again, there was no control group, so the result cannot be separated from placebo response, natural ups and downs of the condition or other influences.

The two person intravenous study

In 2025, researchers gave two healthy adults intravenous infusions of BPC-157 and monitored blood tests and vital signs Human ⁹. They reported no side effects and no changes in the markers they measured. Two people cannot establish that a drug is safe. If neither of them happens to experience a rare side effect, that says almost nothing about what might happen when thousands of people are exposed. It is a useful early observation and nothing more.

Have there been proper clinical trials?

Not of the kind needed to support the claims made online. The early Pliva work in ulcerative colitis never produced published results. A randomised phase 2 trial in acute hamstring strain, registered as NCT07437547, is listed as recruiting 120 participants from February 2026 and compares BPC-157 with placebo. If it completes and is published, it will be the first properly designed efficacy trial in people. No results have been posted.

Drug development cannot jump from animal models to widespread internet use and then treat that use as proof that it works.

Does BPC-157 heal tendons?

In animals, several studies suggest better tendon outcomes. In humans, there is no good randomised evidence that BPC-157 heals tendon injuries. Both statements are true at once, and the same applies to ligament healing, muscle tears, bone repair and most other recovery claims made for it. The preclinical story is plausible and interesting; human confirmation is largely missing.

Is BPC-157 safe?

Not enough is known to say. That is different from saying it has been shown to be dangerous, which has not been established either. The problem is uncertainty: small studies reporting no side effects involve far too few people to detect uncommon, delayed or dose related harm.

Three concerns deserve stating. BPC-157 promotes blood vessel growth in animals, and what long term stimulation of that kind might do to an undetected tumour has never been studied; it is a theoretical risk, unexamined rather than excluded. Almost all material sold to consumers is made outside pharmaceutical standards, and independent analyses of research grade peptides have found wrong peptide content, truncated sequences, residual solvents and bacterial endotoxin. And injecting anything outside medical supervision carries its own infection and injury risks.

The US FDA has stated that it holds little or no safety information for BPC-157 by the routes proposed for compounding, and has raised concerns about immune reactions, peptide related impurities and characterising the active ingredient ¹⁰. BPC-157 has since been taken off that list because its nomination was withdrawn, which is a procedural step, not a finding of safety.

What happened at the FDA in July 2026?

On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee considered BPC-157, for ulcerative colitis, alongside KPV, TB-500 and MOTS-c, as substances nominated for use by compounding pharmacies ¹¹. News reports put the committee's vote at 8 to 6, with one abstention, in favour of recommending that BPC-157 be allowed on the list of substances pharmacies may compound from ¹².

That vote is advice to the FDA, not a decision, and the FDA had not announced one when this article was written. Even if it follows the committee, being allowed in pharmacy compounding is not the same as FDA approval as a medicine, which requires the controlled trials BPC-157 does not have.

Why online testimonials are not enough

Someone gets injured, starts BPC-157, and six weeks later feels better. It is understandable for them to conclude that BPC-157 healed them. But injuries heal with time. People rest, start physiotherapy, change their training and take other medicines; pain comes and goes; and expectations shape how people report symptoms. That is why controlled trials exist. The control group shows what happens to similar people who do not get the treatment, and without one, separating an effect from coincidence is very hard. A hundred convincing anecdotes can be less useful than one well designed randomised trial.

Why BPC-157 is still worth researching

Scepticism is not dismissal. BPC-157 is interesting precisely because the preclinical findings are so broad, and if even part of that effect carried over reliably to people, it could deserve serious development ¹³. That is an argument for proper trials, not for pretending they have already happened. The 2026 Pharmaceutics review describes BPC-157 as underdeveloped as a medicine, without validated formulations, established clinical dosing or a completed phase 2 trial. That is less exciting than "the Wolverine peptide heals injuries", and a great deal more accurate.

Is BPC-157 an approved medicine?

No. In the UK it has no MHRA marketing authorisation, and supplied or promoted for human use it counts as a medicinal product under the Human Medicines Regulations 2012, which makes such sale unlawful. It is not FDA approved in the United States. In sport it is prohibited at all times under the WADA category for non approved substances. Regulatory status can change when evidence changes; at the moment, the evidence is not there.

Frequently asked questions

Does BPC-157 work?

In laboratory and animal studies it has produced enough interesting results to justify further research. Whether it works in people has not been tested in any controlled trial.

Has BPC-157 been studied in humans?

Barely. Fewer than 30 people across three small uncontrolled studies, in knee pain, bladder pain and a two person safety pilot. A randomised trial in hamstring strain is registered but has not reported.

What does BPC stand for?

Body Protection Compound. The name reflects the protective effects reported in animal studies of the stomach and gut.

Is BPC-157 safe?

Not established. Human exposure in published research is far too small to show a reliable safety profile, and products sold online are unregulated.

Is BPC-157 approved in the UK?

No. It has no MHRA marketing authorisation, and supplying it for human use is unlawful under the Human Medicines Regulations 2012.

How does BPC-157 differ from TB-500?

They are unrelated molecules. TB-500 is usually a short fragment sold under the name of thymosin beta-4, a natural 43 amino acid protein that regulates actin inside cells. Thymosin beta-4 has reached phase 3 trials in people, although without a clean result; BPC-157 has not reached controlled human trials at all. The two are often combined as the Wolverine stack, which has never been tested as a combination in people.

More peptide questions

References

Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.

1. Sikiric P et al. (2006). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. Inflammopharmacology.PubMed · DOI · View study in BioRx
2. Seiwerth S et al. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology.PubMed · DOI · View study in BioRx
3. Vasireddi N et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal.PubMed · DOI · View study in BioRx
4. Chang CH et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology.PubMed · DOI · View study in BioRx
5. Chang CH et al. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules.PubMed · DOI · View study in BioRx
6. Mateescu DM et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics.PubMed · DOI · View study in BioRx
7. Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine.PubMed · View study in BioRx
8. Lee E, Walker C, Ayadi B (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine.PubMed · View study in BioRx
9. Lee E, Burgess K (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine.PubMed · View study in BioRx
10. FDA, Certain bulk drug substances for use in compounding that may present significant safety risks
11. FDA, Pharmacy Compounding Advisory Committee meeting, 23 and 24 July 2026
12. STAT news report on the committee vote, 23 July 2026
13. McGuire FP et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med 2025